Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scripps Research scientists develop new tools to unveil mystery of the 'glycome'

11.06.2012
Technique will help scientists understand how cells' common sugar molecules influence inflammation, cancer metastasis, and related conditions

Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body.

The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.

The new study, which appears online in Nature Chemical Biology on June 10, 2012, describes compounds that selectively block the attachment to the cell of two types of sugar building blocks, sialic acid and fucose, which are found at the tips of cell surface glycans and can be critical to cell function.

"We've developed the first compounds that can easily get into cells and selectively shut down the enzymes that decorate glycans with sialic acid or fucose," said Scripps Research Professor James C. Paulson, the senior author of the new report.

One of the Least Understood Domains of Biology

The "glycome"—the full set of sugar molecules in living things and even viruses—has been one of the least understood domains of biology. While the glycome encodes key information that regulates things such as cell trafficking events and cell signaling, this information has been relatively difficult to "decode." Unlike proteins, which are relatively straightforward translations of genetic information, functional sugars have no clear counterparts or "templates" in the genome. Their building blocks are simple, diet-derived sugar molecules, and their builders are a set of about 250 enzymes known broadly as glycosyltransferases. Characterizing these enzymes is essential to understanding the glycome. But one of the most basic tools of enzyme characterization—a specific enzyme inhibitor that can work in cell cultures and in lab animals—has been lacking for most glycosyltransferase families.

Three years ago, Cory Rillahan, a PhD candidate working in Paulson's laboratory, set out to find compounds that can specifically inhibit two important families of glycosyltransferases: the fucosyltransferases, which attach fucose groups, and the sialyltransferases, which attach sialic acids.

"They tend to be the most biologically relevant, because they attach these sugar units at the very tips of the glycan chains, which is where proteins on other cells bind to them," said Rillahan.

Rillahan began a quest by developing a screening technique that could be used to sift rapidly through chemical compound libraries to find strong inhibitors of these two enzyme families. This high-throughput screening technique was described last year in the journal Angewandte Chemie. But while Rillahan waited to get access to a larger compound library, he read of a more focused, rational-design strategy that Canadian researchers had used to devise inhibitors of a different glycosyltransferase.

Using 'Imposter' Molecules

Rillahan quickly adapted this broad strategy against sialyl- and fucosyltransferases in work described in the new study.

Normally an enzyme such as a fucosyltransferase grabs its payload—fucose, in this case—from a larger donor molecule, then attaches the small sugar to a glycan structure. Rillahan created fucose analogs, "impostor" molecules that can be readily taken up by this process, but then jam it. When one of these fucose analogs gets into a cell, it is processed into a donor molecule and grabbed by a fucosyltransferase—but can't be attached to a glycan. Rillahan also designed sialic acid analogs that have the same spoofing effects against sialyltransferases.

These analogs act as traditional enzyme inhibitors in the sense that they bind to their enzyme targets and thereby block the enzymes from performing their normal function. But Rillahan found that his analogs have a second effect on their targeted enzyme pathways. They lead to an overabundance of unusable, analog-containing donor molecules in a cell; and that overabundance triggers a powerful feedback mechanism that dials down the production of new donor molecules—the only functional ones.

"The cell is fooled into thinking that it has enough of these donor molecules and doesn't need to make more," Rillahan said. With the combination of this shutoff signal and the analogs' physical blocking of enzymes, affected cells in the experiments soon lost nearly all the fucoses and sialic acids from their glycans.

Therapeutic Potential

One important glycan that is normally decorated with fucoses and sialic acids is known as Sialyl Lewis X. It is highly expressed on activated white blood cells and helps them grab cell-adhesion molecules called selectins on the inner walls of blood vessels. The velcro-like effect causes the circulating white blood cells to roll to a stop against the vessel wall, whereupon they exit the bloodstream and infiltrate local tissues. The overexpression of Sialyl Lewis X or the selectins that grab this structure has been linked to chronic inflammation conditions and various cancers. Rillahan treated test cells with his best fucose and sialic acid analogs, and showed that virtually all the sialic acids and fucoses disappeared from Sialyl Lewis X molecules within a few days. Such cells were much less likely to roll to a stop on selectin-coated surfaces—suggesting that they would be much less likely to cause inflammation or cancer metastasis.

Paulson, Rillahan, and their colleagues now are working to reproduce the effects of these enzyme-inhibiting analogs in laboratory mice. "The idea is to show that these compounds can be effective in reducing the cell trafficking that contributes to inflammation and metastasis, but without harming the animals," Paulson said.

The researchers also plan to use Rillahan's screening technique to sift through large compound libraries, to try to find compounds that inhibit specific enzymes within the sialyltransferase and fucosyltranferase families. Such enzyme-specific inhibitors might have narrower treatment effects and fewer side effects than broader, family-specific inhibitors.

In addition to Paulson and Rillahan, co-authors of the paper, "Global Metabolic Inhibitors of Sialyl- and Fucosyltransferases Remodel the Glycome," are Aristotelis Antonopoulos, Anne Dell, and Stuart M. Haslam of Imperial College, London, who performed mass-spectrometry analyses to confirm the absence of sialic acids and fucoses from treated cells; Roberto Sonon and Parastoo Azadi of the University of Georgia, whose tests demonstrated the feedback-shutdown of donor molecule synthesis in treated cells; and Craig T. Lefort and Klaus Ley of the La Jolla Institute for Allergy and Immunology, who performed the cell rolling tests.

The research was funded in part by the National Institutes of Health.

Mika Ono | EurekAlert!
Further information:
http://www.scripps.edu

More articles from Life Sciences:

nachricht Cnidarians remotely control bacteria
21.09.2017 | Christian-Albrechts-Universität zu Kiel

nachricht Immune cells may heal bleeding brain after strokes
21.09.2017 | NIH/National Institute of Neurological Disorders and Stroke

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Comet or asteroid? Hubble discovers that a unique object is a binary

21.09.2017 | Physics and Astronomy

Cnidarians remotely control bacteria

21.09.2017 | Life Sciences

Monitoring the heart's mitochondria to predict cardiac arrest?

21.09.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>